Allakos Reports 'Positive' Results From Phase 1 Trial of Antibody That Inhibits Mast Cells

MT Newswires Live06-26

Allakos (ALLK) reported "positive" results late Tuesday from its single and multiple ascending phase 1 study of intravenous AK006, a monoclonal antibody that selectively inhibits mast cells, in healthy volunteers.

The company said inappropriate activation of mast cells is a pathogenic driver of multiple diseases, including chronic spontaneous urticaria, food allergy, and asthma.

It said single and multiple doses of up to 720 milligrams were "well tolerated with a favorable safety profile." AK006 achieved serum concentrations consistent with levels demonstrating inhibitory activity in preclinical experiments.

The company said skin biopsies from subjects treated with AK006 showed "high receptor occupancy."

Shares of the company slumped 15% in after-hours activity.

Price: 1.0000, Change: -0.18, Percent Change: -15.25

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2446879543?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-06-26 04:21","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2446879543","market":"us","top_or_hot":-1,"title":"Allakos Reports 'Positive' Results From Phase 1 Trial of Antibody That Inhibits Mast Cells","media":"MT Newswires Live","content":"<html><body><p> Allakos (ALLK) reported \"positive\" results late Tuesday from its single and multiple ascending phase 1 study of intravenous AK006, a monoclonal antibody that selectively inhibits mast cells, in healthy volunteers.</p><p>The company said inappropriate activation of mast cells is a pathogenic driver of multiple diseases, including chronic spontaneous urticaria, food allergy, and asthma.</p><p>It said single and multiple doses of up to 720 milligrams were \"well tolerated with a favorable safety profile.\" AK006 achieved serum concentrations consistent with levels demonstrating inhibitory activity in preclinical experiments.</p><p>The company said skin biopsies from subjects treated with AK006 showed \"high receptor occupancy.\"</p><p>Shares of the company slumped 15% in after-hours activity.</p><p>Price: 1.0000, Change: -0.18, Percent Change: -15.25</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Allakos Reports 'Positive' Results From Phase 1 Trial of Antibody That Inhibits Mast Cells</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAllakos Reports 'Positive' Results From Phase 1 Trial of Antibody That Inhibits Mast Cells\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-06-26 04:21 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.mtnewswires.com/><strong>MT Newswires Live</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Allakos (ALLK) reported \"positive\" results late Tuesday from its single and multiple ascending phase 1 study of intravenous AK006, a monoclonal antibody that selectively inhibits mast cells, in ...</p>\n\n<a href=\"https://www.mtnewswires.com/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2446879543","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2446879543","pubTimestamp":1719346896,"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Allakos  reported \"positive\" results late Tuesday from its single and multiple ascending phase 1 study of intravenous AK006, a monoclonal antibody that selectively inhibits mast cells, in healthy volunteers.The company said inappropriate activation of mast cells is a pathogenic driver of multiple diseases, including chronic spontaneous urticaria, food allergy, and asthma.It said single and multiple doses of up to 720 milligrams were \"well tolerated with a favorable safety profile.\" AK006 achieved serum concentrations consistent with levels demonstrating inhibitory activity in preclinical experiments.The company said skin biopsies from subjects treated with AK006 showed \"high receptor occupancy.\"Shares of the company slumped 15% in after-hours activity.Price: 1.0000, Change: -0.18, Percent Change: -15.25","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","ALLK":"Allakos Inc."},"translate_title":"Allakos报告抑制肥大细胞抗体1期试验的“阳性”结果","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ALLK":0.9},"content_text":"Allakos (ALLK) reported \"positive\" results late Tuesday from its single and multiple ascending phase 1 study of intravenous AK006, a monoclonal antibody that selectively inhibits mast cells, in healthy volunteers.The company said inappropriate activation of mast cells is a pathogenic driver of multiple diseases, including chronic spontaneous urticaria, food allergy, and asthma.It said single and multiple doses of up to 720 milligrams were \"well tolerated with a favorable safety profile.\" AK006 achieved serum concentrations consistent with levels demonstrating inhibitory activity in preclinical experiments.The company said skin biopsies from subjects treated with AK006 showed \"high receptor occupancy.\"Shares of the company slumped 15% in after-hours activity.Price: 1.0000, Change: -0.18, Percent Change: -15.25","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.28.1","shortVersion":"4.28.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2446879543"}